MaxCyte, Inc. Revenue 2019–2025
MaxCyte, Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- MaxCyte, Inc. revenue for the quarter ending March 31, 2026 was 4.5 M, a 21.63% decrease year-over-year.
- MaxCyte, Inc. revenue for the twelve months ending March 31, 2026 was 20.7 M, a 1.74% increase year-over-year.
- MaxCyte, Inc. annual revenue for 2025 was 21.0 M, a 5.66% decrease from 2024.
- MaxCyte, Inc. annual revenue for 2024 was 22.2 M, a 13.94% increase from 2023.
- MaxCyte, Inc. annual revenue for 2023 was 19.5 M, a 32.18% decrease from 2022.
- MaxCyte, Inc. annual revenue for 2022 was 28.7 M.
MaxCyte, Inc. (MXCT) — Frequently Asked Questions
MaxCyte, Inc. (MXCT) is a publicly traded US company. It has a market capitalization of $122M. In fiscal 2025 it reported revenue of $21M and net income of -$45M. Explore MXCT's stock price, financial statements, earnings history, margins and key ratios below.
What is MaxCyte, Inc.'s market cap?
MaxCyte, Inc. (MXCT) has a market capitalization of $122M.
What is the MXCT stock price?
MXCT trades at $1.15 (-3.36% on the day).
How much revenue does MaxCyte, Inc. make?
MaxCyte, Inc. reported revenue of $21M in fiscal 2025.
Is MXCT profitable?
In fiscal 2025, MaxCyte, Inc. reported net income of -$45M.